Drugs / Army Liposome Formulation containing QS-21
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06863142 | Apr 2025 → Jul 2026 overdue | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Army Liposome Formulation containing QS-21 | “The adjuvant, Army Liposome Formulation containing QS-21 (ALFQ), was developed, and provided by the Walter Reed Army Institute of Research (WRAIR).” NCT06863142 ↗ |
| Known as | ALFQ | “The ALFQ adjuvant is a sterile suspension that contains monophosphoryl 3-deacyl Lipid A \[3D-PHAD(R)\] and QS-21” NCT06863142 ↗ |
| Modality | Other / unclassified | “The ALFQ adjuvant is a sterile suspension” NCT06863142 ↗ |
| Route | Intramuscular | “FluMos-v2 with and without ALFQ adjuvant will be administered intramuscularly (IM) in the deltoid muscle via needle and syringe” NCT06863142 ↗ |